Emergent BioSolutions | EBS - Passivo Circulante





Passivo Circulante Alterar Data
Acadia Pharmaceuticals USD 332.22M 29.22M 2026-09
Akebia Therapeutics USD 162.35M 1.48M 2026-09
ALKERMES USD 651.93M 10.16M 2026-09
Alnylam Pharmaceuticals USD 2.06B 550.49M 2026-09
Amarin USD 175.14M 10.94M 2026-09
ANI Pharmaceuticals USD 328.72M 45.06M 2026-09
BioMarin Pharmaceutical USD 1.6B 59.17M 2026-09
Coherus Biosciences USD 75.51M 56.82M 2026-06
Emergent BioSolutions USD 651.3M 12.7M 2023-12
Exelixis USD 411.88M 49.95M 2026-09
Glaxosmithkline GBP 20.72B 1.71B 2026-09
Heron Therapeutics USD 92.14M 1.63M 2026-06
Ionis Pharmaceuticals USD 315.64M 401.36M 2026-06
Ironwood Pharmaceuticals USD 34.73M 1.88M 2026-09
Lexicon Pharmaceuticals USD 9.9M 10.97M 2026-03
Lonza CHF 3.57B 421M 2025-12
Merck USD 28.8B 1.07B 2026-09
Moderna USD 2.03B 506M 2026-09
Myriad Genetics USD 130.7M 500K 2026-06
Nektar Therapeutics USD 57.71M 4.17M 2026-03
Neurocrine Biosciences USD 984.6M 110.1M 2026-09
Pacira USD 126.1M 4.08M 2026-09
Pfizer USD 31.73B 920M 2026-09
PTC Therapeutics USD 776.08M 5.01M 2026-09
Sanofi EUR 29.77B 2.16B 2026-09
Sarepta Therapeutics USD 656.35M 153.44M 2026-09
United Therapeutics USD 624.3M 16.5M 2026-09
Vanda Pharmaceuticals USD 145.16M 27.29M 2025-12